• Male

Dr. ir. J. van den Bossche PhD

Position: Postdoc
Main activities: Research
Specialisation: Metabolic/epigenetic crosstalk in macrophages
foto
Focus of research:

Metabolic/epigenetic crosstalk in macrophages

In addition to their function in host defense, macrophages secure tissue homeostasis and dampen inflammatory responses. To carry out these seemingly contrasting functions, macrophages show high plasticity and adopt a spectrum of polarization states, including M1 and M2 cells. Editing macrophage (re)polarization is emerging as a new therapeutic approach. For example, reprogramming tumor-promoting ‘M2-like’ tumor-associated macrophages into anti-tumor ‘M1-like’ cells is being tested as a cancer treatment. Conversely, the treatment of chronic inflammatory diseases such as atherosclerosis will benefit from the repolarization of inflammatory into anti-inflammatory macrophages.

Both metabolic and epigenetic mechanisms are emerging as crucial controllers of macrophages. Our research aims to target macrophage metabolism (Jeroen Baardman) and epigenetics (Rosario Luque-Martin) to improve disease outcome. Moreover, we are tackling the fundamental question how epigenetics could serve as a bridge between macrophage metabolism and its phenotype.
 

 

AMC themes: Cardiovascular Diseases, Infection & Immunity
Departments: Medical Biochemistry
Ahmed M, de Winther MPJ, van den Bossche J, Epigenetic mechanisms of macrophage activation in type 2 dilabetes. IMMUNOBIOLOGY 2017;222 (10):937-943 [PubMed]
Bernelot Moens SJ, Neele AE, Kroon J, van der Valk FM, van den Bossche J, Hoeksema MA, Hoogeveen RM, Schnitzler JG, Baccara-Dinet MT, Manvelian G, de Winther MPJ, Stroes ESG, PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. EUR HEART J 2017;38 (20):1584-1593 [PubMed]
de Ronde MWJ, Kok MGM, Moerland PD, van den Bossche J, Neele AE, Halliani A, van der Made I, de Winther MPJ, Meijers JCM, Creemers EE, Pinto-Sietsma SJ, High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis. ATHEROSCLEROSIS 2017;263:377-384 [PubMed]
Neele AE, Prange KH, Hoeksema MA, van der Velden S, Lucas T, Dimmeler S, Lutgens E, van den Bossche J, de Winther MP, Macrophage Kdm6b controls the pro-fibrotic transcriptome signature of foam cells. EPIGENOMICS-UK 2017;9 (4):383-391 [PubMed]
van den Berg SM, van Dam AD, Kusters PJH, Beckers L, den Toom M, van der Velden S, van den Bossche J, van Die I, Boon MR, Rensen PCN, Lutgens E, de Winther MPJ, Helminth antigens counteract a rapid high-fat diet-induced decrease in adipose tissue eosinophils. J MOL ENDOCRINOL 2017;59 (3):245-255 [PubMed]
van den Bossche J, O'Neill LA, Menon D, Macrophage Immunometabolism: Where Are We (Going)?. TRENDS IMMUNOL 2017;38 (6):395-406 [PubMed]
Winkels H, Meiler S, Smeets E, Lievens D, Engel D, Spitz C, Bürger C, Rinne P, Beckers L, Dandl A, Reim S, Ahmadsei M, van den Bossche J, Holdt LM, Megens RTA, Schmitt M, de Winther M, Biessen EA, Borst J, Faussner A, Weber C, Lutgens E, Gerdes N, CD70 limits atherosclerosis and promotes macrophage function. THROMB HAEMOSTASIS 2017;117 (1):164-175 [PubMed]
Boshuizen MCS, Hoeksema MA, Neele AE, van der Velden S, Hamers AAJ, van den Bossche J, Lutgens E, de Winther MPJ, Interferon-β promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. CYTOKINE 2016;77:220-226 [PubMed]
Boshuizen MCS, Neele AE, Gijbels MJJ, van der Velden S, Hoeksema MA, Forman RA, Muller W, van den Bossche J, de Winther MPJ, Myeloid interferon-γ receptor deficiency does not affect atherosclerosis in LDLR(-/-) mice. ATHEROSCLEROSIS 2016;246:325-333 [PubMed]
van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, Luque-Martin R, Chen HJ, Boshuizen MCS, Ahmed M, Hoeksema MA, de Vos AF, de Winther MPJ, Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. CELL REP 2016;17 (3):684-696 [PubMed]
van der Valk FM, Bekkering S, Kroon J, Yeang C, van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LAB, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ESG, Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. CIRCULATION 2016;134 (8):611-624 [PubMed]
van der Valk FM, Schulte DM, Meiler S, Tang J, Zheng KH, van den Bossche J, Seijkens T, Laudes M, de Winther M, Lutgens E, Alaarg A, Metselaar JM, Dallinga-Thie GM, Mulder WJM, Stroes ESG, Hamers AAJ, Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. NANOMED-NANOTECHNOL 2016;12 (6):1463-1470 [PubMed]
Baardman J, Licht I, de Winther MPJ, van den Bossche J, Metabolic-epigenetic crosstalk in macrophage activation. EPIGENOMICS-UK 2015;7 (7):1155-1164 [PubMed]
Hoeksema MA, Scicluna BP, Boshuizen MCS, van der Velden S, Neele AE, van den Bossche J, Matlung HL, van den Berg TK, Goossens P, de Winther MPJ, IFN-γ priming of macrophages represses a part of the inflammatory program and attenuates neutrophil recruitment. J IMMUNOL 2015;194 (8):3909-3916 [PubMed]
Neele AE, van den Bossche J, Hoeksema MA, de Winther MPJ, Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis. EUR J PHARMACOL 2015;763 (Part A):79-89 [PubMed]
van den Bossche J, Baardman J, de Winther MPJ, Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis. JOVE-J VIS EXP 2015;2015 (105):e53424 [PubMed]
Hoeksema MA, Gijbels MJJ, van den Bossche J, van der Velden S, Sijm A, Neele AE, Seijkens T, Stöger JL, Meiler S, Boshuizen MCS, Dallinga-Thie GM, Levels JHM, Boon L, Mullican SE, Spann NJ, Cleutjens JP, Glass CK, Lazar MA, de Vries CJM, Biessen EAL, Daemen MJAP, Lutgens E, de Winther MPJ, Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO MOL MED 2014;6 (9):1124-1132 [PubMed]
van den Bossche J, Neele AE, Hoeksema MA, de Heij F, Boshuizen MCS, van der Velden S, de Boer VC, Reedquist KA, de Winther MPJ, Inhibiting epigenetic enzymes to improve atherogenic macrophage functions. BIOCHEM BIOPH RES CO 2014;455 (3-4):396-402 [PubMed]
van den Bossche J, Neele AE, Hoeksema MA, de Winther MPJ, Macrophage polarization: the epigenetic point of view. CURR OPIN LIPIDOL 2014;25 (5):367-373 [PubMed]
Boon MR, van den Berg SAA, Wang Y, van den Bossche J, Karkampouna S, Bauwens M, de Saint-Hubert M, van der Horst G, Vukicevic S, de Winther MPJ, Havekes LM, Jukema JW, Tamsma JT, van der Pluijm G, van Dijk KW, Rensen PCN, BMP7 Activates Brown Adipose Tissue and Reduces Diet-Induced Obesity Only at Subthermoneutrality. PLOS ONE 2013;8 (9):e74083-(12 p.) [PubMed]
Schmieder A, Schledzewski K, Michel J, Schönhaar K, Morias Y, Bosschaerts T, van den Bossche J, Dorny P, Sauer A, Sticht C, Géraud C, Waibler Z, Beschin A, Goerdt S, The CD20 homolog Ms4a8a integrates pro- and anti-inflammatory signals in novel M2-like macrophages and is expressed in parasite infection. EUR J IMMUNOL 2012;42 (11):2971-2982 [PubMed]
van den Bossche J, Lamers WH, Koehler ES, Geuns JMC, Alhonen L, Uimari A, Pirnes-Karhu S, van Overmeire E, Morias Y, Brys L, Vereecke L, de Baetselier P, van Ginderachter JA, Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J LEUKOCYTE BIOL 2012;91 (5):685-699 [PubMed]
van den Bossche J, Malissen B, Mantovani A, de Baetselier P, van Ginderachter JA, Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. BLOOD 2012;119 (7):1623-1633 [PubMed]
Laoui D, Movahedi K, van Overmeire E, van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, de Baetselier P, van Ginderachter JA, Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. INT J DEV BIOL 2011;55 (7-9):861-867 [PubMed]
Laoui D, van Overmeire E, Movahedi K, van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, de Baetselier P, van Ginderachter JA, Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. IMMUNOBIOLOGY 2011;216 (11):1192-1202 [PubMed]
Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, van den Bossche J, Mack M, Pipeleers D, In't Veld P, de Baetselier P, van Ginderachter JA, Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. CANCER RES 2010;70 (14):5728-5739 [PubMed]
van den Bossche J, Bogaert P, van Hengel J, Guérin CJ, Berx G, Movahedi K, van den Bergh R, Pereira-Fernandes A, Geuns JMC, Pircher H, Dorny P, Grooten J, de Baetselier P, van Ginderachter JA, Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. BLOOD 2009;114 (21):4664-4674 [PubMed]
Movahedi K, Guilliams M, van den Bossche J, van den Bergh R, Gysemans C, Beschin A, de Baetselier P, van Ginderachter JA, Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. BLOOD 2008;111 (8):4233-4244 [PubMed]
van Ginderachter JA, Movahedi K, van den Bossche J, de Baetselier P, Macrophages, PPARs, and Cancer. PPAR RES 2008;2008:169414 [PubMed]
Key publications

van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, Luque-Martin R, Chen HJ, Boshuizen MCS, Ahmed M, Hoeksema MA, de Vos AF, de Winther MPJ, Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. CELL REP 2016;17 (3):684-696 [PubMed]
van der Valk FM, Bekkering S, Kroon J, Yeang C, van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LAB, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ESG, Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. CIRCULATION 2016;134 (8):611-624 [PubMed]
Baardman J, Licht I, de Winther MPJ, van den Bossche J, Metabolic-epigenetic crosstalk in macrophage activation. EPIGENOMICS-UK 2015;7 (7):1155-1164 [PubMed]
Hoeksema MA, Gijbels MJJ, van den Bossche J, van der Velden S, Sijm A, Neele AE, Seijkens T, Stöger JL, Meiler S, Boshuizen MCS, Dallinga-Thie GM, Levels JHM, Boon L, Mullican SE, Spann NJ, Cleutjens JP, Glass CK, Lazar MA, de Vries CJM, Biessen EAL, Daemen MJAP, Lutgens E, de Winther MPJ, Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO MOL MED 2014;6 (9):1124-1132 [PubMed]
van den Bossche J, Bogaert P, van Hengel J, Guérin CJ, Berx G, Movahedi K, van den Bergh R, Pereira-Fernandes A, Geuns JMC, Pircher H, Dorny P, Grooten J, de Baetselier P, van Ginderachter JA, Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. BLOOD 2009;114 (21):4664-4674 [PubMed]


All Publications

Curriculum Vitae

Education
PhD (2006-2011):
Department of Molecular and Cellular Interactions (Myeloid Cell Immunology Lab), VIB; Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
Regulation and function of alternatively activated macrophage markers; a focus on E-cadherin.

Promotor: Prof. Dr. ir. Jo A. Van Ginderachter and Prof. Dr. Patrick De Baetselier
Finished October 28, 2011 with greatest distinction, ‘summa cum laude’.

Bachelor/Master (2001-2006):
Master in bio-engineering, specialization in Cell and Gene biotechnology -Medical biotechnology, with greatest distinction at Vrije Universiteit Brussel
Master thesis: E-cadherin as a novel marker for alternatively activated macrophages.
Promotor: Prof. Dr. P. De Baetselier and Prof. Dr. ir. J.A. Van Ginderachter

2012: Course Laboratory Animal Science (Art. 9, NL)
2011: Course Effective Oral Communication by Jean-luc Doumont
2009: Course Scientific Writing by Jane Fraser
2007: Diploma Laboratory Animal Science (FELASA Cat. B)

Research experience
Academic Medical Center (AMC) / University of Amsterdam, The Netherlands
Senior Scientist, June 2012 - current

Perform research on epigenetic-metabolic interplay in macrophage activation within the Experimental Vascular Biology group at the Department of Medical Biochemistry. Supervise three PhD students.

University of Tübingen, Germany
Postdoc / Guest Scientist, November 2011 – May 2012

Wrote grants in order to start a new study in sports immunology within the ‘Institute of Clinical and Experimental Transfusion Medicine’ of Prof. H. Northoff.
Performed research on humans with the goal to understand the phenomenon of exercise-induced immunosuppression.

 

Vrije Universiteit Brussel, Belgium
PhD, October 2006 – October 2011

Performed fundamental scientific research on alternative macrophage activation, which resulted in the publication of 6 first-author and 6 co-author publications in high ranking international scientific journals and allowed me to give lectures at international meetings.
During this work I managed my own research projects in an independent way and acquired a broad range of skills, including cellular and molecular biology techniques, the experience to work with laboratory animals (mice), and presentation skills.

Publications

  • Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, Luque-Martin R, Chen HJ, Boshuizen MC, Ahmed M, Hoeksema MA, de Vos AF, de Winther MP. Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. Cell Reports. 2016 Oct 11;17(3):684-696. doi: 10.1016/j.celrep.2016.09.008.
    *Published as a ‘Featured Article’ with a preview by Luke O’neill entitled ‘A metabolic roadblock in inflammatory macrophages.’
  • Winkels H, Meiler S, Smeets E, Lievens D, Engel D, Spitz C, Bürger C, Rinne P, Beckers L, Dandl A, Reim S, Ahmadsei M, Van den Bossche J, Holdt LM, Megens RT, Schmitt M, de Winther M, Biessen EA, Borst J, Faussner A, Weber C, Lutgens E, Gerdes N. CD70 limits atherosclerosis and promotes macrophage function. Thromb Haemost. 2016 Oct 27.
  • Ahmed M, de Winther MP, Van den Bossche J. Epigenetic mechanisms of macrophage activation in type 2 diabetes. Immunobiology. 2016 Sep 3. pii: S0171-2985(16)30358-8. doi: 10.1016/j.imbio.2016.08.011
  • van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838. Epub 2016 Aug 5
  • van der Valk FM, Schulte DM, Meiler S, Tang J, Zheng KH, Van den Bossche J, Seijkens T, Laudes M, de Winther M, Lutgens E, Alaarg A, Metselaar JM, Dallinga-Thie GM, Mulder WJ, Stroes ES, Hamers AA. Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. Nanomedicine. 2016 Mar 23. pii: S1549-9634(16)30014-4. doi: 10.1016/j.nano.2016.02.022.
  • Boshuizen MC, Neele AE, Gijbels MJ, van der Velden S, Hoeksema MA, Forman RA, Muller W, Van den Bossche J, de Winther MP. Myeloid interferon-γ receptor deficiency does not affect atherosclerosis in LDLR(-/-) mice. Atherosclerosis. 2016 Mar;246:325-33. doi: 10.1016/j.atherosclerosis.2016.01.026.
  • Baardman J, Licht I, de Winther MP, Van den Bossche J. Metabolic-epigenetic crosstalk in macrophage activation. Epigenomics. 2015 Oct;7(7):1155-64. doi: 10.2217/epi.15.71
  • Van den Bossche J, Baardman J, de Winther MP. Metabolic characterization of polarized M1 and M2 bone marrow-derived macrophages using real-time extracellular flux analysis. J Vis Exp. 2015 Nov 28;(105). doi: 10.3791/53424.
  • Boshuizen MC, Hoeksema MA, Neele AE, van der Velden S, Hamers AA, Van den Bossche J, Lutgens E, de Winther MP. Interferon- promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. Cytokine. 2015 Sep 28. pii: S1043-4666(15)30069-7. doi: 10.1016/j.cyto.2015.09.016.
  • Van den Bossche J, Laoui D, Naessens T, Smits HH, Hokke CH, Stijlemans B, Grooten J, De Baetselier P, Van Ginderachter JA. E-cadherin expression in macrophages dampens their inflammatory responsiveness in vitro, but does not modulate M2-regulated pathologies in vivo. Sci Rep. 2015 Jul 31;5:12599. doi: 10.1038/srep12599.
  • Neele AE*, Van den Bossche J*, Hoeksema MA, de Winther MP. Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis. Eur J Pharmacol. 2015 May 21. pii: S0014-2999(15)00466-5. doi: 10.1016/j.ejphar.2015.03.101.
  • *Equal contribution shared first author
  • Hoeksema MA, Scicluna BP, Boshuizen MC, van der Velden S, Neele AE, Van den Bossche J, Matlung HL, van den Berg TK, Goossens P, de Winther MP. IFN-γ Priming of Macrophages Represses a Part of the Inflammatory Program and Attenuates Neutrophil Recruitment. J Immunol. 2015 Apr 15;194(8):3909-16. doi: 10.4049/jimmunol.1402077.
  • Van den Bossche J, Neele AE, Hoeksema MA, de Heij F, Boshuizen MC, van der Velden S, de Boer VC, Reedquist KA, de Winther MP. Inhibiting epigenetic enzymes to improve atherogenic macrophage functions. Biochemical and Biophysical Research Communications. 2014 Dec 12;455(3-4):396-402. doi: 10.1016/j.bbrc.2014.11.029.
  • Van den Bossche J, Neele AE, Hoeksema MA, de Winther MP. Macrophage polarization: the epigenetic point of wiex. Current Opinion in Lipidology. 2014 Oct;25(5):367-73
  • Hoeksema MA, Gijbels MJJ, Van den Bossche J, van der Velden S, Sijm A, Neele AE, Seijkens T, Stöger JL, Meiler S, Boshuizen MCS, Boon L, Mullican SE, Spann NJ, Cleutjens JP, Glass CK, Lazar MA, de Vries CJ, Biessen EAL, Daemen MJAP, Lutgens E, de Winther MP. Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Molecular Medicine. 2014 Jul 9;6(9):1124-32. doi: 10.15252/emmm.201404170.
  • Boon MR, van den Berg SA, Wang Y, Van den Bossche J, Karkampouna S, Bauwens M, De Saint-Hubert M, van der Horst G, Vukicevic S, de Winther MP, Havekes LM, Jukema JW, Tamsma JT, van der Pluijm G, van Dijk KW, Rensen PC. BMP7 activates brown adipose tissue and reduces diet-induced obesity only at subthermoneutrality. PLoS One. 2013 Sep 16;8(9):e74083
  • Van den Bossche J & Van Ginderachter JA. E-cadherin: from epithelial glue to immunological regulator. European Journal of Immunology. 2013 Jan;43(1):34-7. doi: 10.1002/eji.201243168
  • Schmieder A, Schledzewski K, Michel J, Schönhaar K, Morias Y, Bosschaerts T, Van den Bossche J, Dorny P, Sauer A, Sticht C, Géraud C, Waibler Z, Beschin A, Goerdt S. The CD20 homolog Ms4a8a integrates pro- and anti-inflammatory signals in novel M2-like macrophages and is expressed in parasite infection. European Journal of Immunology. 2012 Jul 18. doi: 10.1002/eji.201142331
  • Van den Bossche J, Laoui D, Morias Y, Movahedi K, Raes R, De Baetselier P, Van Ginderachter JA. Claudin-1, claudin-2 and claudin-11 genes differentially associate with distinct types of anti-inflammatory macrophages in vitro and with parasite- and tumor-elicited macrophages in vivo. Scandinavian Jounral of Immunology. 2012 Jun;75(6):588-98.
  • Van den Bossche J, Lamers WH, Koehler ES, Geuns JMC, Alhonen L, Uimari A, Pirnes-Karhu S, De Baetselier P, Van Ginderachter JA. Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. Journal of Leukocyte Biology. 2012 May;91(5):685-99. *Published as a ‘Pivotal Advance Article’ with an editorial comment by Gobert and Wilson
  • Van den Bossche J, Malissen B, Mantovani A, De Baetselier P, Van Ginderachter JA. Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DC. Blood. 2012 Feb 16;119(7):1623-33.
  • Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P and Van Ginderachter JA. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology. 2011 Nov;216(11):1192-202.
  • Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology. 2011; 55(7-8-9):861-867.
  • Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P and Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research. 2010 Jul 15;70(14):5728-39.
  • Van den Bossche J, Bogaert P, van Hengel J, Guérin CJ, Berx G, Movahedi K, Van den Bergh R, Pereira-Fernandes A, Geuns JM, Pircher H, Dorny P, Grooten J, De Baetselier P, Van Ginderachter JA. Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood. 2009 Nov 19;114(21):4664-74. *Published with an opening ‘Inside Blood’ comment by Sica and Mantovani, Blood, 2009.
  • Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233–4244.
  • Van Ginderachter JA, Movahedi K, Van den Bossche J, De Baetselier P. Macrophages, PPARs and Cancer. PPAR Research. 2008;2008:199414.

Teaching and leadership

  • Promotor of Jeroen Baardman during his PhD on ‘Targeting macrophage metabolism in atherosclerosis’ (2015-current)
  • Co-promotor and supervisor of Rosario Luque-Martin during her PhD on ‘Epigenetic control of macrophage activation in disease’ (2015-current)
  • Supervisor of Master student internship “Metabolic control of macrophage plasticity.” by Iris Licht (2014-2015)
  • Supervisor of Master student internship “Glycolysis causes an inability of macrophages to repolarize from M1 towards M2 phenotype.” by Natasja Otto (2013-2014)
  • Mentoring Annette Neele during her PhD on ‘Epigenetic regulation of macrophages during atherogenesis (2012-current)
  • Supervisor of Master student internship “Effect of epigenetic enzymes on atherogenic macrophage functions” by Femke de Heij (2012-2013)
  • Supervisor of the Master thesis entitled “Function of E-cadherin in alternatively activated macrophages” by Anna Pereira-Fernandes (2008-2009)
  • Teaching several integrated practicals for Biology and Bio-engineering Master students (2009-2011).

Participation in conferences

  • “Nitric oxide-dependent mitochondrial dysfunction prevents repolarization of inflammatory macrophages” Summer Frontiers ‘Systems Biology of Innate Immunity’ , Nijmegen, The Netherlands, September 7-9, 2016. Oral presentation
  • “Nitric oxide-dependent mitochondrial dysfunction prevents repolarization of inflammatory macrophages” Cell Symposia: 100 years of phagocytes , Sicily, Italy, September 19-22, 2016. Poster presentation“Macrophage NO production induces mitochondrial dysfunction and blunts repolarization to M2” Keystone Symposium: Immunometabolism in Immune Function and Inflammatory Disease. Banff, Canada, February 21-25, 2016. Poster presentation“HDAC inhibition improves atherogenic macrophage function and affects cellular metabolism” 3rd International Conference on ImmunoMetabolism: Molecular and Cellular Immunology of Metabolism, Chania, Greece, September 24-29, 2015. Oral & poster presentation
  • “Targeting epigenetics to improve atherogenic macrophage functions and disease outcome” 21th Scandinavian Atherosclerosis Conference, Humlebaek, Denmark, April 13-16, 2015. Oral presentation
  • “Epigenetic and metabolic control of macrophages in atherosclerosis” Keystone Symposium: Dendritic Cells and Macrophages Reunited. Montreal, Canada, March 8-13, 2015. Poster presentation
  • “Targeting Hdac3 limits foam cell formation and improves atherosclerotic plaque stability” 82nd congress of the European Atherosclerosis society. Madrid, Spain, June 1-3, 2014. Oral presentation
  • “HDAC inhibition improves atherogenic macrophage function and cellular metabolism” abcam meeting. Metabolism and Immunity: A rediscovered frontier. Dublin, Ireland, May 29-30, 2014. Oral presentation“Epigenetic control through histone modifications regulates macrophages during atherosclerosis” Conference on epigenetics and cancer, Barcelona, Spain, November 21-22, 2013. Poster presentation
  • “Polyamines control M1/M2 macrophage activation – possible implications for metabolic syndrome” Keystone Symposiaum: Metabolic Control of Inflammation and Immunity. Breckenridge, CO, January 21-26, 2013. Poster presentation
  • “Polyamines stimulate the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory cytokines” 25th Anual Meeting of the European Macrophage and Dendritic Cell Society. Brussels, Belgium, September 22-24, 2011. Poster presentation
  • “Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes” Keystone Symposium: The Macrophage: Intersection of pathogenic and protective inflammation. Banff, Canada, February 15, 2010. Oral presentation
  • “Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes” 2nd European Congress of Immunology. Berlin, Germany, September 14, 2009. Poster presentation
  • “E-cadherin as a novel marker for alternatively activated macrophages (M2a)” Allergy and Asthma Symposium: Bridging Innate and Adaptive Immunity. Ghent, Belgium, May 28-29 2009. Poster presentation
  • “E-cadherin as a novel marker for alternatively activated macrophages” 1st European Society for Organ Transplantation. Brussels, Belgium, March 13, 2009. Oral presentation
  • 22nd Anual Meeting of the European Macrophage and Dendritic Cell Society. Brescia, Italy, September, 2008. Poster presentation
  • VIB Science Club Molecular and Translational Medicine. Brussels, Belgium, December 12, 2007. Oral presentation
  • VIB Seminar. Blankenberge, Belgium, March 2, 2007. Oral presentation

Fellowships and Awards

  • Personal VENI Postdoc grant from NWO, 2014 (€250.000)
  • Personal Junior Postdoc grant from hartstichting.nl, 2013 (€277.120)
  • Personal doctoral grants of the prestigious “Fonds voor Wetenschappelijk Onderzoek (FWO) / Belgian National Fund for Scientific Research”, 2006-2008 and 2008-2010 (€100.000)
  • Keystone Symposia Scholarship, 2014 ($1.200)
  • Seahorse Bioscience travel award for the Keystone Symosium ‘Immunometabolism in Immune Function and Inflammatory Disease, 2016 ($500)
  • Travel grant for the 3rd International Conference on ImmunoMetabolism: Molecular and Cellular Immunology of Metabolism, 2015 ($500)
  • Roche ‘Refresh your Research’ price (€500)
  • EFIS travel scholarship for 2nd European Congress of Immunology, Berlin, Germany, September, 2009.
  • Vereniging Ingenieurs Brussel (VIrBr) award for best master thesis Bio-Engineering, 2006

Memberships

  • Dutch Society for Immunology (NVVI)
  • European Macrophage & Dendritic Cell Society (EMDS)
  • Belgian Immunological Society (BIS)
  • Belgian Association for Cancer Research (BACR)
  • International Society of Exercise and Immunology (ISEI)
  • Belgian Society for Cell and Developmental Biology (BSCDB)
     

 

Research programmes

Prof. dr. M.P.J. de Winther PhD (Macrophage regulation in cardiovascular disease)

Other research related activities
  • None reported
Current research funding
  • None reported